Global Urological Cancer Therapeutics Drugs Market Growth 2022-2028
The report requires updating with new data and is sent in 48 hours after order is placed.
As the global economy mends, the 2021 growth of Urological Cancer Therapeutics Drugs will have significant change from previous year. According to our (LP Information) latest study, the global Urological Cancer Therapeutics Drugs market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Urological Cancer Therapeutics Drugs market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Urological Cancer Therapeutics Drugs market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Urological Cancer Therapeutics Drugs market, reaching US$ million by the year 2028. As for the Europe Urological Cancer Therapeutics Drugs landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Urological Cancer Therapeutics Drugs players cover Novartis, Pfizer, Johnson & Johnson, and AstraZeneca, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Urological Cancer Therapeutics Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
As the global economy mends, the 2021 growth of Urological Cancer Therapeutics Drugs will have significant change from previous year. According to our (LP Information) latest study, the global Urological Cancer Therapeutics Drugs market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Urological Cancer Therapeutics Drugs market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Urological Cancer Therapeutics Drugs market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Urological Cancer Therapeutics Drugs market, reaching US$ million by the year 2028. As for the Europe Urological Cancer Therapeutics Drugs landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Urological Cancer Therapeutics Drugs players cover Novartis, Pfizer, Johnson & Johnson, and AstraZeneca, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Urological Cancer Therapeutics Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
- Xofigo (radium Ra 223 dichloride)
- Jevtana (cabazitaxel)
- Inlyta (axitinib)
- Votrient (pazopanib hydrochloride)
- Sutent (sunitinib malate)
- Zytiga (abiraterone acetate)
- Xtandi (enzalutamide)
- Opdivo (nivolumab)
- Provenge (sipuleucel-T)
- Hospital
- Medical Research Laboratory
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Novartis
- Pfizer
- Johnson & Johnson
- AstraZeneca
- Astellas
- Bristol-Myers Squibb
- Abbott Laboratories
- Celgene Corporation
- Dendreon Corporation
- Ferring Pharmaceuticals
- GlaxoSmithKline plc
- Indevus Pharmaceuticals Inc
- Ipsen
- Roche Healthcare
- Sanofi S.A.
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Urological Cancer Therapeutics Drugs Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Urological Cancer Therapeutics Drugs by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Urological Cancer Therapeutics Drugs by Country/Region, 2017, 2022 & 2028
2.2 Urological Cancer Therapeutics Drugs Segment by Type
2.2.1 Xofigo (radium Ra 223 dichloride)
2.2.2 Jevtana (cabazitaxel)
2.2.3 Inlyta (axitinib)
2.2.4 Votrient (pazopanib hydrochloride)
2.2.5 Sutent (sunitinib malate)
2.2.6 Zytiga (abiraterone acetate)
2.2.7 Xtandi (enzalutamide)
2.2.8 Opdivo (nivolumab)
2.2.9 Provenge (sipuleucel-T)
2.3 Urological Cancer Therapeutics Drugs Sales by Type
2.3.1 Global Urological Cancer Therapeutics Drugs Sales Market Share by Type (2017-2022)
2.3.2 Global Urological Cancer Therapeutics Drugs Revenue and Market Share by Type (2017-2022)
2.3.3 Global Urological Cancer Therapeutics Drugs Sale Price by Type (2017-2022)
2.4 Urological Cancer Therapeutics Drugs Segment by Application
2.4.1 Hospital
2.4.2 Medical Research Laboratory
2.4.3 Others
2.5 Urological Cancer Therapeutics Drugs Sales by Application
2.5.1 Global Urological Cancer Therapeutics Drugs Sale Market Share by Application (2017-2022)
2.5.2 Global Urological Cancer Therapeutics Drugs Revenue and Market Share by Application (2017-2022)
2.5.3 Global Urological Cancer Therapeutics Drugs Sale Price by Application (2017-2022)
3 GLOBAL UROLOGICAL CANCER THERAPEUTICS DRUGS BY COMPANY
3.1 Global Urological Cancer Therapeutics Drugs Breakdown Data by Company
3.1.1 Global Urological Cancer Therapeutics Drugs Annual Sales by Company (2020-2022)
3.1.2 Global Urological Cancer Therapeutics Drugs Sales Market Share by Company (2020-2022)
3.2 Global Urological Cancer Therapeutics Drugs Annual Revenue by Company (2020-2022)
3.2.1 Global Urological Cancer Therapeutics Drugs Revenue by Company (2020-2022)
3.2.2 Global Urological Cancer Therapeutics Drugs Revenue Market Share by Company (2020-2022)
3.3 Global Urological Cancer Therapeutics Drugs Sale Price by Company
3.4 Key Manufacturers Urological Cancer Therapeutics Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Urological Cancer Therapeutics Drugs Product Location Distribution
3.4.2 Players Urological Cancer Therapeutics Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR UROLOGICAL CANCER THERAPEUTICS DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Urological Cancer Therapeutics Drugs Market Size by Geographic Region (2017-2022)
4.1.1 Global Urological Cancer Therapeutics Drugs Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Urological Cancer Therapeutics Drugs Annual Revenue by Geographic Region
4.2 World Historic Urological Cancer Therapeutics Drugs Market Size by Country/Region (2017-2022)
4.2.1 Global Urological Cancer Therapeutics Drugs Annual Sales by Country/Region (2017-2022)
4.2.2 Global Urological Cancer Therapeutics Drugs Annual Revenue by Country/Region
4.3 Americas Urological Cancer Therapeutics Drugs Sales Growth
4.4 APAC Urological Cancer Therapeutics Drugs Sales Growth
4.5 Europe Urological Cancer Therapeutics Drugs Sales Growth
4.6 Middle East & Africa Urological Cancer Therapeutics Drugs Sales Growth
5 AMERICAS
5.1 Americas Urological Cancer Therapeutics Drugs Sales by Country
5.1.1 Americas Urological Cancer Therapeutics Drugs Sales by Country (2017-2022)
5.1.2 Americas Urological Cancer Therapeutics Drugs Revenue by Country (2017-2022)
5.2 Americas Urological Cancer Therapeutics Drugs Sales by Type
5.3 Americas Urological Cancer Therapeutics Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Urological Cancer Therapeutics Drugs Sales by Region
6.1.1 APAC Urological Cancer Therapeutics Drugs Sales by Region (2017-2022)
6.1.2 APAC Urological Cancer Therapeutics Drugs Revenue by Region (2017-2022)
6.2 APAC Urological Cancer Therapeutics Drugs Sales by Type
6.3 APAC Urological Cancer Therapeutics Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Urological Cancer Therapeutics Drugs by Country
7.1.1 Europe Urological Cancer Therapeutics Drugs Sales by Country (2017-2022)
7.1.2 Europe Urological Cancer Therapeutics Drugs Revenue by Country (2017-2022)
7.2 Europe Urological Cancer Therapeutics Drugs Sales by Type
7.3 Europe Urological Cancer Therapeutics Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Urological Cancer Therapeutics Drugs by Country
8.1.1 Middle East & Africa Urological Cancer Therapeutics Drugs Sales by Country (2017-2022)
8.1.2 Middle East & Africa Urological Cancer Therapeutics Drugs Revenue by Country (2017-2022)
8.2 Middle East & Africa Urological Cancer Therapeutics Drugs Sales by Type
8.3 Middle East & Africa Urological Cancer Therapeutics Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Urological Cancer Therapeutics Drugs
10.3 Manufacturing Process Analysis of Urological Cancer Therapeutics Drugs
10.4 Industry Chain Structure of Urological Cancer Therapeutics Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Urological Cancer Therapeutics Drugs Distributors
11.3 Urological Cancer Therapeutics Drugs Customer
12 WORLD FORECAST REVIEW FOR UROLOGICAL CANCER THERAPEUTICS DRUGS BY GEOGRAPHIC REGION
12.1 Global Urological Cancer Therapeutics Drugs Market Size Forecast by Region
12.1.1 Global Urological Cancer Therapeutics Drugs Forecast by Region (2023-2028)
12.1.2 Global Urological Cancer Therapeutics Drugs Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Urological Cancer Therapeutics Drugs Forecast by Type
12.7 Global Urological Cancer Therapeutics Drugs Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis Urological Cancer Therapeutics Drugs Product Offered
13.1.3 Novartis Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer Urological Cancer Therapeutics Drugs Product Offered
13.2.3 Pfizer Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 Johnson & Johnson
13.3.1 Johnson & Johnson Company Information
13.3.2 Johnson & Johnson Urological Cancer Therapeutics Drugs Product Offered
13.3.3 Johnson & Johnson Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Johnson & Johnson Main Business Overview
13.3.5 Johnson & Johnson Latest Developments
13.4 AstraZeneca
13.4.1 AstraZeneca Company Information
13.4.2 AstraZeneca Urological Cancer Therapeutics Drugs Product Offered
13.4.3 AstraZeneca Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 AstraZeneca Main Business Overview
13.4.5 AstraZeneca Latest Developments
13.5 Astellas
13.5.1 Astellas Company Information
13.5.2 Astellas Urological Cancer Therapeutics Drugs Product Offered
13.5.3 Astellas Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Astellas Main Business Overview
13.5.5 Astellas Latest Developments
13.6 Bristol-Myers Squibb
13.6.1 Bristol-Myers Squibb Company Information
13.6.2 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Product Offered
13.6.3 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Bristol-Myers Squibb Main Business Overview
13.6.5 Bristol-Myers Squibb Latest Developments
13.7 Abbott Laboratories
13.7.1 Abbott Laboratories Company Information
13.7.2 Abbott Laboratories Urological Cancer Therapeutics Drugs Product Offered
13.7.3 Abbott Laboratories Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Abbott Laboratories Main Business Overview
13.7.5 Abbott Laboratories Latest Developments
13.8 Celgene Corporation
13.8.1 Celgene Corporation Company Information
13.8.2 Celgene Corporation Urological Cancer Therapeutics Drugs Product Offered
13.8.3 Celgene Corporation Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Celgene Corporation Main Business Overview
13.8.5 Celgene Corporation Latest Developments
13.9 Dendreon Corporation
13.9.1 Dendreon Corporation Company Information
13.9.2 Dendreon Corporation Urological Cancer Therapeutics Drugs Product Offered
13.9.3 Dendreon Corporation Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Dendreon Corporation Main Business Overview
13.9.5 Dendreon Corporation Latest Developments
13.10 Ferring Pharmaceuticals
13.10.1 Ferring Pharmaceuticals Company Information
13.10.2 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Product Offered
13.10.3 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Ferring Pharmaceuticals Main Business Overview
13.10.5 Ferring Pharmaceuticals Latest Developments
13.11 GlaxoSmithKline plc
13.11.1 GlaxoSmithKline plc Company Information
13.11.2 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Product Offered
13.11.3 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 GlaxoSmithKline plc Main Business Overview
13.11.5 GlaxoSmithKline plc Latest Developments
13.12 Indevus Pharmaceuticals Inc
13.12.1 Indevus Pharmaceuticals Inc Company Information
13.12.2 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Product Offered
13.12.3 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Indevus Pharmaceuticals Inc Main Business Overview
13.12.5 Indevus Pharmaceuticals Inc Latest Developments
13.13 Ipsen
13.13.1 Ipsen Company Information
13.13.2 Ipsen Urological Cancer Therapeutics Drugs Product Offered
13.13.3 Ipsen Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Ipsen Main Business Overview
13.13.5 Ipsen Latest Developments
13.14 Roche Healthcare
13.14.1 Roche Healthcare Company Information
13.14.2 Roche Healthcare Urological Cancer Therapeutics Drugs Product Offered
13.14.3 Roche Healthcare Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 Roche Healthcare Main Business Overview
13.14.5 Roche Healthcare Latest Developments
13.15 Sanofi S.A.
13.15.1 Sanofi S.A. Company Information
13.15.2 Sanofi S.A. Urological Cancer Therapeutics Drugs Product Offered
13.15.3 Sanofi S.A. Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.15.4 Sanofi S.A. Main Business Overview
13.15.5 Sanofi S.A. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Urological Cancer Therapeutics Drugs Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Urological Cancer Therapeutics Drugs by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Urological Cancer Therapeutics Drugs by Country/Region, 2017, 2022 & 2028
2.2 Urological Cancer Therapeutics Drugs Segment by Type
2.2.1 Xofigo (radium Ra 223 dichloride)
2.2.2 Jevtana (cabazitaxel)
2.2.3 Inlyta (axitinib)
2.2.4 Votrient (pazopanib hydrochloride)
2.2.5 Sutent (sunitinib malate)
2.2.6 Zytiga (abiraterone acetate)
2.2.7 Xtandi (enzalutamide)
2.2.8 Opdivo (nivolumab)
2.2.9 Provenge (sipuleucel-T)
2.3 Urological Cancer Therapeutics Drugs Sales by Type
2.3.1 Global Urological Cancer Therapeutics Drugs Sales Market Share by Type (2017-2022)
2.3.2 Global Urological Cancer Therapeutics Drugs Revenue and Market Share by Type (2017-2022)
2.3.3 Global Urological Cancer Therapeutics Drugs Sale Price by Type (2017-2022)
2.4 Urological Cancer Therapeutics Drugs Segment by Application
2.4.1 Hospital
2.4.2 Medical Research Laboratory
2.4.3 Others
2.5 Urological Cancer Therapeutics Drugs Sales by Application
2.5.1 Global Urological Cancer Therapeutics Drugs Sale Market Share by Application (2017-2022)
2.5.2 Global Urological Cancer Therapeutics Drugs Revenue and Market Share by Application (2017-2022)
2.5.3 Global Urological Cancer Therapeutics Drugs Sale Price by Application (2017-2022)
3 GLOBAL UROLOGICAL CANCER THERAPEUTICS DRUGS BY COMPANY
3.1 Global Urological Cancer Therapeutics Drugs Breakdown Data by Company
3.1.1 Global Urological Cancer Therapeutics Drugs Annual Sales by Company (2020-2022)
3.1.2 Global Urological Cancer Therapeutics Drugs Sales Market Share by Company (2020-2022)
3.2 Global Urological Cancer Therapeutics Drugs Annual Revenue by Company (2020-2022)
3.2.1 Global Urological Cancer Therapeutics Drugs Revenue by Company (2020-2022)
3.2.2 Global Urological Cancer Therapeutics Drugs Revenue Market Share by Company (2020-2022)
3.3 Global Urological Cancer Therapeutics Drugs Sale Price by Company
3.4 Key Manufacturers Urological Cancer Therapeutics Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Urological Cancer Therapeutics Drugs Product Location Distribution
3.4.2 Players Urological Cancer Therapeutics Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR UROLOGICAL CANCER THERAPEUTICS DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Urological Cancer Therapeutics Drugs Market Size by Geographic Region (2017-2022)
4.1.1 Global Urological Cancer Therapeutics Drugs Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Urological Cancer Therapeutics Drugs Annual Revenue by Geographic Region
4.2 World Historic Urological Cancer Therapeutics Drugs Market Size by Country/Region (2017-2022)
4.2.1 Global Urological Cancer Therapeutics Drugs Annual Sales by Country/Region (2017-2022)
4.2.2 Global Urological Cancer Therapeutics Drugs Annual Revenue by Country/Region
4.3 Americas Urological Cancer Therapeutics Drugs Sales Growth
4.4 APAC Urological Cancer Therapeutics Drugs Sales Growth
4.5 Europe Urological Cancer Therapeutics Drugs Sales Growth
4.6 Middle East & Africa Urological Cancer Therapeutics Drugs Sales Growth
5 AMERICAS
5.1 Americas Urological Cancer Therapeutics Drugs Sales by Country
5.1.1 Americas Urological Cancer Therapeutics Drugs Sales by Country (2017-2022)
5.1.2 Americas Urological Cancer Therapeutics Drugs Revenue by Country (2017-2022)
5.2 Americas Urological Cancer Therapeutics Drugs Sales by Type
5.3 Americas Urological Cancer Therapeutics Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Urological Cancer Therapeutics Drugs Sales by Region
6.1.1 APAC Urological Cancer Therapeutics Drugs Sales by Region (2017-2022)
6.1.2 APAC Urological Cancer Therapeutics Drugs Revenue by Region (2017-2022)
6.2 APAC Urological Cancer Therapeutics Drugs Sales by Type
6.3 APAC Urological Cancer Therapeutics Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Urological Cancer Therapeutics Drugs by Country
7.1.1 Europe Urological Cancer Therapeutics Drugs Sales by Country (2017-2022)
7.1.2 Europe Urological Cancer Therapeutics Drugs Revenue by Country (2017-2022)
7.2 Europe Urological Cancer Therapeutics Drugs Sales by Type
7.3 Europe Urological Cancer Therapeutics Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Urological Cancer Therapeutics Drugs by Country
8.1.1 Middle East & Africa Urological Cancer Therapeutics Drugs Sales by Country (2017-2022)
8.1.2 Middle East & Africa Urological Cancer Therapeutics Drugs Revenue by Country (2017-2022)
8.2 Middle East & Africa Urological Cancer Therapeutics Drugs Sales by Type
8.3 Middle East & Africa Urological Cancer Therapeutics Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Urological Cancer Therapeutics Drugs
10.3 Manufacturing Process Analysis of Urological Cancer Therapeutics Drugs
10.4 Industry Chain Structure of Urological Cancer Therapeutics Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Urological Cancer Therapeutics Drugs Distributors
11.3 Urological Cancer Therapeutics Drugs Customer
12 WORLD FORECAST REVIEW FOR UROLOGICAL CANCER THERAPEUTICS DRUGS BY GEOGRAPHIC REGION
12.1 Global Urological Cancer Therapeutics Drugs Market Size Forecast by Region
12.1.1 Global Urological Cancer Therapeutics Drugs Forecast by Region (2023-2028)
12.1.2 Global Urological Cancer Therapeutics Drugs Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Urological Cancer Therapeutics Drugs Forecast by Type
12.7 Global Urological Cancer Therapeutics Drugs Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis Urological Cancer Therapeutics Drugs Product Offered
13.1.3 Novartis Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer Urological Cancer Therapeutics Drugs Product Offered
13.2.3 Pfizer Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 Johnson & Johnson
13.3.1 Johnson & Johnson Company Information
13.3.2 Johnson & Johnson Urological Cancer Therapeutics Drugs Product Offered
13.3.3 Johnson & Johnson Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Johnson & Johnson Main Business Overview
13.3.5 Johnson & Johnson Latest Developments
13.4 AstraZeneca
13.4.1 AstraZeneca Company Information
13.4.2 AstraZeneca Urological Cancer Therapeutics Drugs Product Offered
13.4.3 AstraZeneca Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 AstraZeneca Main Business Overview
13.4.5 AstraZeneca Latest Developments
13.5 Astellas
13.5.1 Astellas Company Information
13.5.2 Astellas Urological Cancer Therapeutics Drugs Product Offered
13.5.3 Astellas Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Astellas Main Business Overview
13.5.5 Astellas Latest Developments
13.6 Bristol-Myers Squibb
13.6.1 Bristol-Myers Squibb Company Information
13.6.2 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Product Offered
13.6.3 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Bristol-Myers Squibb Main Business Overview
13.6.5 Bristol-Myers Squibb Latest Developments
13.7 Abbott Laboratories
13.7.1 Abbott Laboratories Company Information
13.7.2 Abbott Laboratories Urological Cancer Therapeutics Drugs Product Offered
13.7.3 Abbott Laboratories Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Abbott Laboratories Main Business Overview
13.7.5 Abbott Laboratories Latest Developments
13.8 Celgene Corporation
13.8.1 Celgene Corporation Company Information
13.8.2 Celgene Corporation Urological Cancer Therapeutics Drugs Product Offered
13.8.3 Celgene Corporation Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Celgene Corporation Main Business Overview
13.8.5 Celgene Corporation Latest Developments
13.9 Dendreon Corporation
13.9.1 Dendreon Corporation Company Information
13.9.2 Dendreon Corporation Urological Cancer Therapeutics Drugs Product Offered
13.9.3 Dendreon Corporation Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Dendreon Corporation Main Business Overview
13.9.5 Dendreon Corporation Latest Developments
13.10 Ferring Pharmaceuticals
13.10.1 Ferring Pharmaceuticals Company Information
13.10.2 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Product Offered
13.10.3 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Ferring Pharmaceuticals Main Business Overview
13.10.5 Ferring Pharmaceuticals Latest Developments
13.11 GlaxoSmithKline plc
13.11.1 GlaxoSmithKline plc Company Information
13.11.2 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Product Offered
13.11.3 GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 GlaxoSmithKline plc Main Business Overview
13.11.5 GlaxoSmithKline plc Latest Developments
13.12 Indevus Pharmaceuticals Inc
13.12.1 Indevus Pharmaceuticals Inc Company Information
13.12.2 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Product Offered
13.12.3 Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 Indevus Pharmaceuticals Inc Main Business Overview
13.12.5 Indevus Pharmaceuticals Inc Latest Developments
13.13 Ipsen
13.13.1 Ipsen Company Information
13.13.2 Ipsen Urological Cancer Therapeutics Drugs Product Offered
13.13.3 Ipsen Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Ipsen Main Business Overview
13.13.5 Ipsen Latest Developments
13.14 Roche Healthcare
13.14.1 Roche Healthcare Company Information
13.14.2 Roche Healthcare Urological Cancer Therapeutics Drugs Product Offered
13.14.3 Roche Healthcare Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 Roche Healthcare Main Business Overview
13.14.5 Roche Healthcare Latest Developments
13.15 Sanofi S.A.
13.15.1 Sanofi S.A. Company Information
13.15.2 Sanofi S.A. Urological Cancer Therapeutics Drugs Product Offered
13.15.3 Sanofi S.A. Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.15.4 Sanofi S.A. Main Business Overview
13.15.5 Sanofi S.A. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Urological Cancer Therapeutics Drugs Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Urological Cancer Therapeutics Drugs Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Xofigo (radium Ra 223 dichloride)
Table 4. Major Players of Jevtana (cabazitaxel)
Table 5. Major Players of Inlyta (axitinib)
Table 6. Major Players of Votrient (pazopanib hydrochloride)
Table 7. Major Players of Sutent (sunitinib malate)
Table 8. Major Players of Zytiga (abiraterone acetate)
Table 9. Major Players of Xtandi (enzalutamide)
Table 10. Major Players of Opdivo (nivolumab)
Table 11. Major Players of Provenge (sipuleucel-T)
Table 12. Global Urological Cancer Therapeutics Drugs Sales by Type (2017-2022) & (K MT)
Table 13. Global Urological Cancer Therapeutics Drugs Sales Market Share by Type (2017-2022)
Table 14. Global Urological Cancer Therapeutics Drugs Revenue by Type (2017-2022) & ($ million)
Table 15. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Type (2017-2022)
Table 16. Global Urological Cancer Therapeutics Drugs Sale Price by Type (2017-2022) & (USD/MT)
Table 17. Global Urological Cancer Therapeutics Drugs Sales by Application (2017-2022) & (K MT)
Table 18. Global Urological Cancer Therapeutics Drugs Sales Market Share by Application (2017-2022)
Table 19. Global Urological Cancer Therapeutics Drugs Revenue by Application (2017-2022)
Table 20. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Application (2017-2022)
Table 21. Global Urological Cancer Therapeutics Drugs Sale Price by Application (2017-2022) & (USD/MT)
Table 22. Global Urological Cancer Therapeutics Drugs Sales by Company (2020-2022) & (K MT)
Table 23. Global Urological Cancer Therapeutics Drugs Sales Market Share by Company (2020-2022)
Table 24. Global Urological Cancer Therapeutics Drugs Revenue by Company (2020-2022) ($ Millions)
Table 25. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Company (2020-2022)
Table 26. Global Urological Cancer Therapeutics Drugs Sale Price by Company (2020-2022) & (USD/MT)
Table 27. Key Manufacturers Urological Cancer Therapeutics Drugs Producing Area Distribution and Sales Area
Table 28. Players Urological Cancer Therapeutics Drugs Products Offered
Table 29. Urological Cancer Therapeutics Drugs Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 30. New Products and Potential Entrants
Table 31. Mergers & Acquisitions, Expansion
Table 32. Global Urological Cancer Therapeutics Drugs Sales by Geographic Region (2017-2022) & (K MT)
Table 33. Global Urological Cancer Therapeutics Drugs Sales Market Share Geographic Region (2017-2022)
Table 34. Global Urological Cancer Therapeutics Drugs Revenue by Geographic Region (2017-2022) & ($ millions)
Table 35. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Geographic Region (2017-2022)
Table 36. Global Urological Cancer Therapeutics Drugs Sales by Country/Region (2017-2022) & (K MT)
Table 37. Global Urological Cancer Therapeutics Drugs Sales Market Share by Country/Region (2017-2022)
Table 38. Global Urological Cancer Therapeutics Drugs Revenue by Country/Region (2017-2022) & ($ millions)
Table 39. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Country/Region (2017-2022)
Table 40. Americas Urological Cancer Therapeutics Drugs Sales by Country (2017-2022) & (K MT)
Table 41. Americas Urological Cancer Therapeutics Drugs Sales Market Share by Country (2017-2022)
Table 42. Americas Urological Cancer Therapeutics Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 43. Americas Urological Cancer Therapeutics Drugs Revenue Market Share by Country (2017-2022)
Table 44. Americas Urological Cancer Therapeutics Drugs Sales by Type (2017-2022) & (K MT)
Table 45. Americas Urological Cancer Therapeutics Drugs Sales Market Share by Type (2017-2022)
Table 46. Americas Urological Cancer Therapeutics Drugs Sales by Application (2017-2022) & (K MT)
Table 47. Americas Urological Cancer Therapeutics Drugs Sales Market Share by Application (2017-2022)
Table 48. APAC Urological Cancer Therapeutics Drugs Sales by Region (2017-2022) & (K MT)
Table 49. APAC Urological Cancer Therapeutics Drugs Sales Market Share by Region (2017-2022)
Table 50. APAC Urological Cancer Therapeutics Drugs Revenue by Region (2017-2022) & ($ Millions)
Table 51. APAC Urological Cancer Therapeutics Drugs Revenue Market Share by Region (2017-2022)
Table 52. APAC Urological Cancer Therapeutics Drugs Sales by Type (2017-2022) & (K MT)
Table 53. APAC Urological Cancer Therapeutics Drugs Sales Market Share by Type (2017-2022)
Table 54. APAC Urological Cancer Therapeutics Drugs Sales by Application (2017-2022) & (K MT)
Table 55. APAC Urological Cancer Therapeutics Drugs Sales Market Share by Application (2017-2022)
Table 56. Europe Urological Cancer Therapeutics Drugs Sales by Country (2017-2022) & (K MT)
Table 57. Europe Urological Cancer Therapeutics Drugs Sales Market Share by Country (2017-2022)
Table 58. Europe Urological Cancer Therapeutics Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 59. Europe Urological Cancer Therapeutics Drugs Revenue Market Share by Country (2017-2022)
Table 60. Europe Urological Cancer Therapeutics Drugs Sales by Type (2017-2022) & (K MT)
Table 61. Europe Urological Cancer Therapeutics Drugs Sales Market Share by Type (2017-2022)
Table 62. Europe Urological Cancer Therapeutics Drugs Sales by Application (2017-2022) & (K MT)
Table 63. Europe Urological Cancer Therapeutics Drugs Sales Market Share by Application (2017-2022)
Table 64. Middle East & Africa Urological Cancer Therapeutics Drugs Sales by Country (2017-2022) & (K MT)
Table 65. Middle East & Africa Urological Cancer Therapeutics Drugs Sales Market Share by Country (2017-2022)
Table 66. Middle East & Africa Urological Cancer Therapeutics Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 67. Middle East & Africa Urological Cancer Therapeutics Drugs Revenue Market Share by Country (2017-2022)
Table 68. Middle East & Africa Urological Cancer Therapeutics Drugs Sales by Type (2017-2022) & (K MT)
Table 69. Middle East & Africa Urological Cancer Therapeutics Drugs Sales Market Share by Type (2017-2022)
Table 70. Middle East & Africa Urological Cancer Therapeutics Drugs Sales by Application (2017-2022) & (K MT)
Table 71. Middle East & Africa Urological Cancer Therapeutics Drugs Sales Market Share by Application (2017-2022)
Table 72. Key Market Drivers & Growth Opportunities of Urological Cancer Therapeutics Drugs
Table 73. Key Market Challenges & Risks of Urological Cancer Therapeutics Drugs
Table 74. Key Industry Trends of Urological Cancer Therapeutics Drugs
Table 75. Urological Cancer Therapeutics Drugs Raw Material
Table 76. Key Suppliers of Raw Materials
Table 77. Urological Cancer Therapeutics Drugs Distributors List
Table 78. Urological Cancer Therapeutics Drugs Customer List
Table 79. Global Urological Cancer Therapeutics Drugs Sales Forecast by Region (2023-2028) & (K MT)
Table 80. Global Urological Cancer Therapeutics Drugs Sales Market Forecast by Region
Table 81. Global Urological Cancer Therapeutics Drugs Revenue Forecast by Region (2023-2028) & ($ millions)
Table 82. Global Urological Cancer Therapeutics Drugs Revenue Market Share Forecast by Region (2023-2028)
Table 83. Americas Urological Cancer Therapeutics Drugs Sales Forecast by Country (2023-2028) & (K MT)
Table 84. Americas Urological Cancer Therapeutics Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 85. APAC Urological Cancer Therapeutics Drugs Sales Forecast by Region (2023-2028) & (K MT)
Table 86. APAC Urological Cancer Therapeutics Drugs Revenue Forecast by Region (2023-2028) & ($ millions)
Table 87. Europe Urological Cancer Therapeutics Drugs Sales Forecast by Country (2023-2028) & (K MT)
Table 88. Europe Urological Cancer Therapeutics Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 89. Middle East & Africa Urological Cancer Therapeutics Drugs Sales Forecast by Country (2023-2028) & (K MT)
Table 90. Middle East & Africa Urological Cancer Therapeutics Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 91. Global Urological Cancer Therapeutics Drugs Sales Forecast by Type (2023-2028) & (K MT)
Table 92. Global Urological Cancer Therapeutics Drugs Sales Market Share Forecast by Type (2023-2028)
Table 93. Global Urological Cancer Therapeutics Drugs Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 94. Global Urological Cancer Therapeutics Drugs Revenue Market Share Forecast by Type (2023-2028)
Table 95. Global Urological Cancer Therapeutics Drugs Sales Forecast by Application (2023-2028) & (K MT)
Table 96. Global Urological Cancer Therapeutics Drugs Sales Market Share Forecast by Application (2023-2028)
Table 97. Global Urological Cancer Therapeutics Drugs Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 98. Global Urological Cancer Therapeutics Drugs Revenue Market Share Forecast by Application (2023-2028)
Table 99. Novartis Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 100. Novartis Urological Cancer Therapeutics Drugs Product Offered
Table 101. Novartis Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 102. Novartis Main Business
Table 103. Novartis Latest Developments
Table 104. Pfizer Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 105. Pfizer Urological Cancer Therapeutics Drugs Product Offered
Table 106. Pfizer Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 107. Pfizer Main Business
Table 108. Pfizer Latest Developments
Table 109. Johnson & Johnson Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 110. Johnson & Johnson Urological Cancer Therapeutics Drugs Product Offered
Table 111. Johnson & Johnson Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 112. Johnson & Johnson Main Business
Table 113. Johnson & Johnson Latest Developments
Table 114. AstraZeneca Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 115. AstraZeneca Urological Cancer Therapeutics Drugs Product Offered
Table 116. AstraZeneca Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 117. AstraZeneca Main Business
Table 118. AstraZeneca Latest Developments
Table 119. Astellas Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 120. Astellas Urological Cancer Therapeutics Drugs Product Offered
Table 121. Astellas Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 122. Astellas Main Business
Table 123. Astellas Latest Developments
Table 124. Bristol-Myers Squibb Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 125. Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Product Offered
Table 126. Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 127. Bristol-Myers Squibb Main Business
Table 128. Bristol-Myers Squibb Latest Developments
Table 129. Abbott Laboratories Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 130. Abbott Laboratories Urological Cancer Therapeutics Drugs Product Offered
Table 131. Abbott Laboratories Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 132. Abbott Laboratories Main Business
Table 133. Abbott Laboratories Latest Developments
Table 134. Celgene Corporation Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 135. Celgene Corporation Urological Cancer Therapeutics Drugs Product Offered
Table 136. Celgene Corporation Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 137. Celgene Corporation Main Business
Table 138. Celgene Corporation Latest Developments
Table 139. Dendreon Corporation Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 140. Dendreon Corporation Urological Cancer Therapeutics Drugs Product Offered
Table 141. Dendreon Corporation Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 142. Dendreon Corporation Main Business
Table 143. Dendreon Corporation Latest Developments
Table 144. Ferring Pharmaceuticals Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 145. Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Product Offered
Table 146. Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 147. Ferring Pharmaceuticals Main Business
Table 148. Ferring Pharmaceuticals Latest Developments
Table 149. GlaxoSmithKline plc Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 150. GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Product Offered
Table 151. GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 152. GlaxoSmithKline plc Main Business
Table 153. GlaxoSmithKline plc Latest Developments
Table 154. Indevus Pharmaceuticals Inc Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 155. Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Product Offered
Table 156. Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 157. Indevus Pharmaceuticals Inc Main Business
Table 158. Indevus Pharmaceuticals Inc Latest Developments
Table 159. Ipsen Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 160. Ipsen Urological Cancer Therapeutics Drugs Product Offered
Table 161. Ipsen Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 162. Ipsen Main Business
Table 163. Ipsen Latest Developments
Table 164. Roche Healthcare Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 165. Roche Healthcare Urological Cancer Therapeutics Drugs Product Offered
Table 166. Roche Healthcare Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 167. Roche Healthcare Main Business
Table 168. Roche Healthcare Latest Developments
Table 169. Sanofi S.A. Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 170. Sanofi S.A. Urological Cancer Therapeutics Drugs Product Offered
Table 171. Sanofi S.A. Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 172. Sanofi S.A. Main Business
Table 173. Sanofi S.A. Latest Developments
Table 1. Urological Cancer Therapeutics Drugs Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Urological Cancer Therapeutics Drugs Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Xofigo (radium Ra 223 dichloride)
Table 4. Major Players of Jevtana (cabazitaxel)
Table 5. Major Players of Inlyta (axitinib)
Table 6. Major Players of Votrient (pazopanib hydrochloride)
Table 7. Major Players of Sutent (sunitinib malate)
Table 8. Major Players of Zytiga (abiraterone acetate)
Table 9. Major Players of Xtandi (enzalutamide)
Table 10. Major Players of Opdivo (nivolumab)
Table 11. Major Players of Provenge (sipuleucel-T)
Table 12. Global Urological Cancer Therapeutics Drugs Sales by Type (2017-2022) & (K MT)
Table 13. Global Urological Cancer Therapeutics Drugs Sales Market Share by Type (2017-2022)
Table 14. Global Urological Cancer Therapeutics Drugs Revenue by Type (2017-2022) & ($ million)
Table 15. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Type (2017-2022)
Table 16. Global Urological Cancer Therapeutics Drugs Sale Price by Type (2017-2022) & (USD/MT)
Table 17. Global Urological Cancer Therapeutics Drugs Sales by Application (2017-2022) & (K MT)
Table 18. Global Urological Cancer Therapeutics Drugs Sales Market Share by Application (2017-2022)
Table 19. Global Urological Cancer Therapeutics Drugs Revenue by Application (2017-2022)
Table 20. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Application (2017-2022)
Table 21. Global Urological Cancer Therapeutics Drugs Sale Price by Application (2017-2022) & (USD/MT)
Table 22. Global Urological Cancer Therapeutics Drugs Sales by Company (2020-2022) & (K MT)
Table 23. Global Urological Cancer Therapeutics Drugs Sales Market Share by Company (2020-2022)
Table 24. Global Urological Cancer Therapeutics Drugs Revenue by Company (2020-2022) ($ Millions)
Table 25. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Company (2020-2022)
Table 26. Global Urological Cancer Therapeutics Drugs Sale Price by Company (2020-2022) & (USD/MT)
Table 27. Key Manufacturers Urological Cancer Therapeutics Drugs Producing Area Distribution and Sales Area
Table 28. Players Urological Cancer Therapeutics Drugs Products Offered
Table 29. Urological Cancer Therapeutics Drugs Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 30. New Products and Potential Entrants
Table 31. Mergers & Acquisitions, Expansion
Table 32. Global Urological Cancer Therapeutics Drugs Sales by Geographic Region (2017-2022) & (K MT)
Table 33. Global Urological Cancer Therapeutics Drugs Sales Market Share Geographic Region (2017-2022)
Table 34. Global Urological Cancer Therapeutics Drugs Revenue by Geographic Region (2017-2022) & ($ millions)
Table 35. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Geographic Region (2017-2022)
Table 36. Global Urological Cancer Therapeutics Drugs Sales by Country/Region (2017-2022) & (K MT)
Table 37. Global Urological Cancer Therapeutics Drugs Sales Market Share by Country/Region (2017-2022)
Table 38. Global Urological Cancer Therapeutics Drugs Revenue by Country/Region (2017-2022) & ($ millions)
Table 39. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Country/Region (2017-2022)
Table 40. Americas Urological Cancer Therapeutics Drugs Sales by Country (2017-2022) & (K MT)
Table 41. Americas Urological Cancer Therapeutics Drugs Sales Market Share by Country (2017-2022)
Table 42. Americas Urological Cancer Therapeutics Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 43. Americas Urological Cancer Therapeutics Drugs Revenue Market Share by Country (2017-2022)
Table 44. Americas Urological Cancer Therapeutics Drugs Sales by Type (2017-2022) & (K MT)
Table 45. Americas Urological Cancer Therapeutics Drugs Sales Market Share by Type (2017-2022)
Table 46. Americas Urological Cancer Therapeutics Drugs Sales by Application (2017-2022) & (K MT)
Table 47. Americas Urological Cancer Therapeutics Drugs Sales Market Share by Application (2017-2022)
Table 48. APAC Urological Cancer Therapeutics Drugs Sales by Region (2017-2022) & (K MT)
Table 49. APAC Urological Cancer Therapeutics Drugs Sales Market Share by Region (2017-2022)
Table 50. APAC Urological Cancer Therapeutics Drugs Revenue by Region (2017-2022) & ($ Millions)
Table 51. APAC Urological Cancer Therapeutics Drugs Revenue Market Share by Region (2017-2022)
Table 52. APAC Urological Cancer Therapeutics Drugs Sales by Type (2017-2022) & (K MT)
Table 53. APAC Urological Cancer Therapeutics Drugs Sales Market Share by Type (2017-2022)
Table 54. APAC Urological Cancer Therapeutics Drugs Sales by Application (2017-2022) & (K MT)
Table 55. APAC Urological Cancer Therapeutics Drugs Sales Market Share by Application (2017-2022)
Table 56. Europe Urological Cancer Therapeutics Drugs Sales by Country (2017-2022) & (K MT)
Table 57. Europe Urological Cancer Therapeutics Drugs Sales Market Share by Country (2017-2022)
Table 58. Europe Urological Cancer Therapeutics Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 59. Europe Urological Cancer Therapeutics Drugs Revenue Market Share by Country (2017-2022)
Table 60. Europe Urological Cancer Therapeutics Drugs Sales by Type (2017-2022) & (K MT)
Table 61. Europe Urological Cancer Therapeutics Drugs Sales Market Share by Type (2017-2022)
Table 62. Europe Urological Cancer Therapeutics Drugs Sales by Application (2017-2022) & (K MT)
Table 63. Europe Urological Cancer Therapeutics Drugs Sales Market Share by Application (2017-2022)
Table 64. Middle East & Africa Urological Cancer Therapeutics Drugs Sales by Country (2017-2022) & (K MT)
Table 65. Middle East & Africa Urological Cancer Therapeutics Drugs Sales Market Share by Country (2017-2022)
Table 66. Middle East & Africa Urological Cancer Therapeutics Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 67. Middle East & Africa Urological Cancer Therapeutics Drugs Revenue Market Share by Country (2017-2022)
Table 68. Middle East & Africa Urological Cancer Therapeutics Drugs Sales by Type (2017-2022) & (K MT)
Table 69. Middle East & Africa Urological Cancer Therapeutics Drugs Sales Market Share by Type (2017-2022)
Table 70. Middle East & Africa Urological Cancer Therapeutics Drugs Sales by Application (2017-2022) & (K MT)
Table 71. Middle East & Africa Urological Cancer Therapeutics Drugs Sales Market Share by Application (2017-2022)
Table 72. Key Market Drivers & Growth Opportunities of Urological Cancer Therapeutics Drugs
Table 73. Key Market Challenges & Risks of Urological Cancer Therapeutics Drugs
Table 74. Key Industry Trends of Urological Cancer Therapeutics Drugs
Table 75. Urological Cancer Therapeutics Drugs Raw Material
Table 76. Key Suppliers of Raw Materials
Table 77. Urological Cancer Therapeutics Drugs Distributors List
Table 78. Urological Cancer Therapeutics Drugs Customer List
Table 79. Global Urological Cancer Therapeutics Drugs Sales Forecast by Region (2023-2028) & (K MT)
Table 80. Global Urological Cancer Therapeutics Drugs Sales Market Forecast by Region
Table 81. Global Urological Cancer Therapeutics Drugs Revenue Forecast by Region (2023-2028) & ($ millions)
Table 82. Global Urological Cancer Therapeutics Drugs Revenue Market Share Forecast by Region (2023-2028)
Table 83. Americas Urological Cancer Therapeutics Drugs Sales Forecast by Country (2023-2028) & (K MT)
Table 84. Americas Urological Cancer Therapeutics Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 85. APAC Urological Cancer Therapeutics Drugs Sales Forecast by Region (2023-2028) & (K MT)
Table 86. APAC Urological Cancer Therapeutics Drugs Revenue Forecast by Region (2023-2028) & ($ millions)
Table 87. Europe Urological Cancer Therapeutics Drugs Sales Forecast by Country (2023-2028) & (K MT)
Table 88. Europe Urological Cancer Therapeutics Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 89. Middle East & Africa Urological Cancer Therapeutics Drugs Sales Forecast by Country (2023-2028) & (K MT)
Table 90. Middle East & Africa Urological Cancer Therapeutics Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 91. Global Urological Cancer Therapeutics Drugs Sales Forecast by Type (2023-2028) & (K MT)
Table 92. Global Urological Cancer Therapeutics Drugs Sales Market Share Forecast by Type (2023-2028)
Table 93. Global Urological Cancer Therapeutics Drugs Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 94. Global Urological Cancer Therapeutics Drugs Revenue Market Share Forecast by Type (2023-2028)
Table 95. Global Urological Cancer Therapeutics Drugs Sales Forecast by Application (2023-2028) & (K MT)
Table 96. Global Urological Cancer Therapeutics Drugs Sales Market Share Forecast by Application (2023-2028)
Table 97. Global Urological Cancer Therapeutics Drugs Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 98. Global Urological Cancer Therapeutics Drugs Revenue Market Share Forecast by Application (2023-2028)
Table 99. Novartis Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 100. Novartis Urological Cancer Therapeutics Drugs Product Offered
Table 101. Novartis Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 102. Novartis Main Business
Table 103. Novartis Latest Developments
Table 104. Pfizer Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 105. Pfizer Urological Cancer Therapeutics Drugs Product Offered
Table 106. Pfizer Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 107. Pfizer Main Business
Table 108. Pfizer Latest Developments
Table 109. Johnson & Johnson Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 110. Johnson & Johnson Urological Cancer Therapeutics Drugs Product Offered
Table 111. Johnson & Johnson Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 112. Johnson & Johnson Main Business
Table 113. Johnson & Johnson Latest Developments
Table 114. AstraZeneca Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 115. AstraZeneca Urological Cancer Therapeutics Drugs Product Offered
Table 116. AstraZeneca Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 117. AstraZeneca Main Business
Table 118. AstraZeneca Latest Developments
Table 119. Astellas Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 120. Astellas Urological Cancer Therapeutics Drugs Product Offered
Table 121. Astellas Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 122. Astellas Main Business
Table 123. Astellas Latest Developments
Table 124. Bristol-Myers Squibb Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 125. Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Product Offered
Table 126. Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 127. Bristol-Myers Squibb Main Business
Table 128. Bristol-Myers Squibb Latest Developments
Table 129. Abbott Laboratories Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 130. Abbott Laboratories Urological Cancer Therapeutics Drugs Product Offered
Table 131. Abbott Laboratories Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 132. Abbott Laboratories Main Business
Table 133. Abbott Laboratories Latest Developments
Table 134. Celgene Corporation Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 135. Celgene Corporation Urological Cancer Therapeutics Drugs Product Offered
Table 136. Celgene Corporation Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 137. Celgene Corporation Main Business
Table 138. Celgene Corporation Latest Developments
Table 139. Dendreon Corporation Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 140. Dendreon Corporation Urological Cancer Therapeutics Drugs Product Offered
Table 141. Dendreon Corporation Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 142. Dendreon Corporation Main Business
Table 143. Dendreon Corporation Latest Developments
Table 144. Ferring Pharmaceuticals Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 145. Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Product Offered
Table 146. Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 147. Ferring Pharmaceuticals Main Business
Table 148. Ferring Pharmaceuticals Latest Developments
Table 149. GlaxoSmithKline plc Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 150. GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Product Offered
Table 151. GlaxoSmithKline plc Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 152. GlaxoSmithKline plc Main Business
Table 153. GlaxoSmithKline plc Latest Developments
Table 154. Indevus Pharmaceuticals Inc Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 155. Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Product Offered
Table 156. Indevus Pharmaceuticals Inc Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 157. Indevus Pharmaceuticals Inc Main Business
Table 158. Indevus Pharmaceuticals Inc Latest Developments
Table 159. Ipsen Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 160. Ipsen Urological Cancer Therapeutics Drugs Product Offered
Table 161. Ipsen Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 162. Ipsen Main Business
Table 163. Ipsen Latest Developments
Table 164. Roche Healthcare Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 165. Roche Healthcare Urological Cancer Therapeutics Drugs Product Offered
Table 166. Roche Healthcare Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 167. Roche Healthcare Main Business
Table 168. Roche Healthcare Latest Developments
Table 169. Sanofi S.A. Basic Information, Urological Cancer Therapeutics Drugs Manufacturing Base, Sales Area and Its Competitors
Table 170. Sanofi S.A. Urological Cancer Therapeutics Drugs Product Offered
Table 171. Sanofi S.A. Urological Cancer Therapeutics Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2020-2022)
Table 172. Sanofi S.A. Main Business
Table 173. Sanofi S.A. Latest Developments
LIST OF FIGURES
Figure 1. Picture of Urological Cancer Therapeutics Drugs
Figure 2. Urological Cancer Therapeutics Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Urological Cancer Therapeutics Drugs Sales Growth Rate 2017-2028 (K MT)
Figure 7. Global Urological Cancer Therapeutics Drugs Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Urological Cancer Therapeutics Drugs Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Xofigo (radium Ra 223 dichloride)
Figure 10. Product Picture of Jevtana (cabazitaxel)
Figure 11. Product Picture of Inlyta (axitinib)
Figure 12. Product Picture of Votrient (pazopanib hydrochloride)
Figure 13. Product Picture of Sutent (sunitinib malate)
Figure 14. Product Picture of Zytiga (abiraterone acetate)
Figure 15. Product Picture of Xtandi (enzalutamide)
Figure 16. Product Picture of Opdivo (nivolumab)
Figure 17. Product Picture of Provenge (sipuleucel-T)
Figure 18. Global Urological Cancer Therapeutics Drugs Sales Market Share by Type in 2021
Figure 19. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Type (2017-2022)
Figure 20. Urological Cancer Therapeutics Drugs Consumed in Hospital
Figure 21. Global Urological Cancer Therapeutics Drugs Market: Hospital (2017-2022) & (K MT)
Figure 22. Urological Cancer Therapeutics Drugs Consumed in Medical Research Laboratory
Figure 23. Global Urological Cancer Therapeutics Drugs Market: Medical Research Laboratory (2017-2022) & (K MT)
Figure 24. Urological Cancer Therapeutics Drugs Consumed in Others
Figure 25. Global Urological Cancer Therapeutics Drugs Market: Others (2017-2022) & (K MT)
Figure 26. Global Urological Cancer Therapeutics Drugs Sales Market Share by Application (2017-2022)
Figure 27. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Application in 2021
Figure 28. Urological Cancer Therapeutics Drugs Revenue Market by Company in 2021 ($ Million)
Figure 29. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Company in 2021
Figure 30. Global Urological Cancer Therapeutics Drugs Sales Market Share by Geographic Region (2017-2022)
Figure 31. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Geographic Region in 2021
Figure 32. Global Urological Cancer Therapeutics Drugs Sales Market Share by Region (2017-2022)
Figure 33. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Country/Region in 2021
Figure 34. Americas Urological Cancer Therapeutics Drugs Sales 2017-2022 (K MT)
Figure 35. Americas Urological Cancer Therapeutics Drugs Revenue 2017-2022 ($ Millions)
Figure 36. APAC Urological Cancer Therapeutics Drugs Sales 2017-2022 (K MT)
Figure 37. APAC Urological Cancer Therapeutics Drugs Revenue 2017-2022 ($ Millions)
Figure 38. Europe Urological Cancer Therapeutics Drugs Sales 2017-2022 (K MT)
Figure 39. Europe Urological Cancer Therapeutics Drugs Revenue 2017-2022 ($ Millions)
Figure 40. Middle East & Africa Urological Cancer Therapeutics Drugs Sales 2017-2022 (K MT)
Figure 41. Middle East & Africa Urological Cancer Therapeutics Drugs Revenue 2017-2022 ($ Millions)
Figure 42. Americas Urological Cancer Therapeutics Drugs Sales Market Share by Country in 2021
Figure 43. Americas Urological Cancer Therapeutics Drugs Revenue Market Share by Country in 2021
Figure 44. United States Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 45. Canada Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 46. Mexico Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 47. Brazil Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 48. APAC Urological Cancer Therapeutics Drugs Sales Market Share by Region in 2021
Figure 49. APAC Urological Cancer Therapeutics Drugs Revenue Market Share by Regions in 2021
Figure 50. China Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 51. Japan Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 52. South Korea Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 53. Southeast Asia Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 54. India Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 55. Australia Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 56. Europe Urological Cancer Therapeutics Drugs Sales Market Share by Country in 2021
Figure 57. Europe Urological Cancer Therapeutics Drugs Revenue Market Share by Country in 2021
Figure 58. Germany Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 59. France Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 60. UK Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 61. Italy Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 62. Russia Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 63. Middle East & Africa Urological Cancer Therapeutics Drugs Sales Market Share by Country in 2021
Figure 64. Middle East & Africa Urological Cancer Therapeutics Drugs Revenue Market Share by Country in 2021
Figure 65. Egypt Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 66. South Africa Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 67. Israel Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 68. Turkey Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 69. GCC Country Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 70. Manufacturing Cost Structure Analysis of Urological Cancer Therapeutics Drugs in 2021
Figure 71. Manufacturing Process Analysis of Urological Cancer Therapeutics Drugs
Figure 72. Industry Chain Structure of Urological Cancer Therapeutics Drugs
Figure 73. Channels of Distribution
Figure 74. Distributors Profiles
Figure 1. Picture of Urological Cancer Therapeutics Drugs
Figure 2. Urological Cancer Therapeutics Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Urological Cancer Therapeutics Drugs Sales Growth Rate 2017-2028 (K MT)
Figure 7. Global Urological Cancer Therapeutics Drugs Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Urological Cancer Therapeutics Drugs Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Xofigo (radium Ra 223 dichloride)
Figure 10. Product Picture of Jevtana (cabazitaxel)
Figure 11. Product Picture of Inlyta (axitinib)
Figure 12. Product Picture of Votrient (pazopanib hydrochloride)
Figure 13. Product Picture of Sutent (sunitinib malate)
Figure 14. Product Picture of Zytiga (abiraterone acetate)
Figure 15. Product Picture of Xtandi (enzalutamide)
Figure 16. Product Picture of Opdivo (nivolumab)
Figure 17. Product Picture of Provenge (sipuleucel-T)
Figure 18. Global Urological Cancer Therapeutics Drugs Sales Market Share by Type in 2021
Figure 19. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Type (2017-2022)
Figure 20. Urological Cancer Therapeutics Drugs Consumed in Hospital
Figure 21. Global Urological Cancer Therapeutics Drugs Market: Hospital (2017-2022) & (K MT)
Figure 22. Urological Cancer Therapeutics Drugs Consumed in Medical Research Laboratory
Figure 23. Global Urological Cancer Therapeutics Drugs Market: Medical Research Laboratory (2017-2022) & (K MT)
Figure 24. Urological Cancer Therapeutics Drugs Consumed in Others
Figure 25. Global Urological Cancer Therapeutics Drugs Market: Others (2017-2022) & (K MT)
Figure 26. Global Urological Cancer Therapeutics Drugs Sales Market Share by Application (2017-2022)
Figure 27. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Application in 2021
Figure 28. Urological Cancer Therapeutics Drugs Revenue Market by Company in 2021 ($ Million)
Figure 29. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Company in 2021
Figure 30. Global Urological Cancer Therapeutics Drugs Sales Market Share by Geographic Region (2017-2022)
Figure 31. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Geographic Region in 2021
Figure 32. Global Urological Cancer Therapeutics Drugs Sales Market Share by Region (2017-2022)
Figure 33. Global Urological Cancer Therapeutics Drugs Revenue Market Share by Country/Region in 2021
Figure 34. Americas Urological Cancer Therapeutics Drugs Sales 2017-2022 (K MT)
Figure 35. Americas Urological Cancer Therapeutics Drugs Revenue 2017-2022 ($ Millions)
Figure 36. APAC Urological Cancer Therapeutics Drugs Sales 2017-2022 (K MT)
Figure 37. APAC Urological Cancer Therapeutics Drugs Revenue 2017-2022 ($ Millions)
Figure 38. Europe Urological Cancer Therapeutics Drugs Sales 2017-2022 (K MT)
Figure 39. Europe Urological Cancer Therapeutics Drugs Revenue 2017-2022 ($ Millions)
Figure 40. Middle East & Africa Urological Cancer Therapeutics Drugs Sales 2017-2022 (K MT)
Figure 41. Middle East & Africa Urological Cancer Therapeutics Drugs Revenue 2017-2022 ($ Millions)
Figure 42. Americas Urological Cancer Therapeutics Drugs Sales Market Share by Country in 2021
Figure 43. Americas Urological Cancer Therapeutics Drugs Revenue Market Share by Country in 2021
Figure 44. United States Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 45. Canada Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 46. Mexico Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 47. Brazil Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 48. APAC Urological Cancer Therapeutics Drugs Sales Market Share by Region in 2021
Figure 49. APAC Urological Cancer Therapeutics Drugs Revenue Market Share by Regions in 2021
Figure 50. China Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 51. Japan Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 52. South Korea Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 53. Southeast Asia Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 54. India Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 55. Australia Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 56. Europe Urological Cancer Therapeutics Drugs Sales Market Share by Country in 2021
Figure 57. Europe Urological Cancer Therapeutics Drugs Revenue Market Share by Country in 2021
Figure 58. Germany Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 59. France Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 60. UK Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 61. Italy Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 62. Russia Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 63. Middle East & Africa Urological Cancer Therapeutics Drugs Sales Market Share by Country in 2021
Figure 64. Middle East & Africa Urological Cancer Therapeutics Drugs Revenue Market Share by Country in 2021
Figure 65. Egypt Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 66. South Africa Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 67. Israel Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 68. Turkey Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 69. GCC Country Urological Cancer Therapeutics Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 70. Manufacturing Cost Structure Analysis of Urological Cancer Therapeutics Drugs in 2021
Figure 71. Manufacturing Process Analysis of Urological Cancer Therapeutics Drugs
Figure 72. Industry Chain Structure of Urological Cancer Therapeutics Drugs
Figure 73. Channels of Distribution
Figure 74. Distributors Profiles
